Completed PHASE1 INTERVENTIONAL 2-arm NCT03814200

A Study to Investigate the Effect of Rifampicin on the Uptake and Breakdown of ACT-246475 in Healthy Subjects

A Single-center, Randomized, Double-blind, Two-period Cross-over Study to Investigate the Effect of a Single Intravenous Dose of Rifampicin on the Pharmacokinetics of ACT-246475 in Healthy Subjects

Sponsor: Viatris Innovation GmbH

Conditions Healthy Subject

Interventions ACT-246475 Rifampicin Saline

Updated 8 times since 2019 Last updated: Jul 1, 2025 Started: Jan 3, 2019 Primary completion: Feb 12, 2019 Completion: Feb 19, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Healthy Subject and is currently completed. Viatris Innovation GmbH leads this study, which shows 8 recorded versions since 2019 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Aug 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Aug 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Dec 2022 — Jul 2024 [monthly]

Completed PHASE1
Mar 2022 — Dec 2022 [monthly]

Completed PHASE1

▶ Show 3 earlier versions

Jan 2021 — Mar 2022 [monthly]

Completed PHASE1
Mar 2019 — Jan 2021 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Feb 2019 — Mar 2019 [monthly]

Recruiting PHASE1

First recorded

Jan 2019

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Viatris Innovation GmbH

Data source: Viatris Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Groningen, Netherlands